Project Grant HT94252410450

GRANT AWARD SUMMARY Mayo Clinic received a $412,429 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to conduct research on novel therapeutic combinations for high-grade serous ovarian cancer (HGSOC). The award period extends from August 1, 2025, through July 31, 2027. The research focuses on developing and mechanistically evaluating drug-induced replication stress markers as therapeutic targets, specifically investigating the...

The National Cancer Institute awarded $581,548 to the University of Southern California under the Cancer Treatment Research program (CFDA 93.395) on June 2, 2026, for a five-year project through May 31, 2031. This Project Grant supports mechanistic research on the therapeutic targeting of WRN (Werner), a DNA helicase protein, in microsatellite-instable (MSI) colorectal cancer cells. The research addresses a significant clinical need by investigating how WRN inhibition triggers cancer cell...

This $399,187 federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will support research at Virginia Commonwealth University to study the role of ATG16L1 isoforms in colorectal cancer health disparities. The key objectives are to: 1) Determine whether the ATG16L1 T300T isoform, which is more predominant in African Americans, promotes more aggressive colorectal tumor growth and metastasis compared to the A300A isoform found more in...

Grant Award Summary The National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded a $658,093 Project Grant to the University of North Carolina at Chapel Hill effective July 13, 2026, with a completion date of June 30, 2031. This research initiative investigates mechanisms by which obesity drives endometrial cancer development and progression, with a focus on evaluating pharmacological and dietary weight-loss interventions as cancer...

Federal Grant Award Summary Oregon Health & Science University received a $401,115 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) on July 10, 2026, with a completion date of June 30, 2028. The award funds development of a patient-derived intestinal organoid system to model gastrointestinal toxicity associated with immune checkpoint inhibitors (ICIs)—monoclonal antibodies targeting PD-1 and CTLA-4 receptors used in cancer...

Federal Project Grant Award Summary The National Cancer Institute awarded a $730,097 Project Grant to the Sloan-Kettering Institute for Cancer Research, effective May 1, 2026 through April 30, 2031, under the Cancer Treatment Research program (CFDA 93.395). This research project focuses on understanding and overcoming chronic inflammation-driven T cell quiescence in gastric adenocarcinoma, a disease representing the fifth leading cause of cancer death globally with rising incidence among younger...

GRANT SUMMARY The National Cancer Institute awarded Weill Medical College of Cornell University a $607,849 Project Grant on August 15, 2025, under the Cancer Treatment Research program (CFDA 93.395) to conduct a five-year research initiative examining mechanisms of genetic and non-genetic resistance to KRAS (Kirsten Rat Sarcoma) inhibition in lung adenocarcinoma and colorectal cancer. The research aims to identify why patients develop resistance to newly emerged mutant-selective and pan-KRAS...

Award Summary The National Institute on Aging (NIA) awarded a $681,020 Project Grant (CFDA 93.866, Aging Research) on June 15, 2026, to Magee-Womens Research Institute and Foundation to conduct biomedical research investigating the microbial regulation of type 2 immunity in ovarian tissue remodeling and fibrosis. The research will be conducted in Pittsburgh, Pennsylvania, with a project completion date of February 28, 2031. The study challenges the conventional understanding of reproductive...

Federal Project Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $463,279 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective July 1, 2026 through June 30, 2031. The award supports research investigating USP1 (ubiquitin-specific peptidase 1) inhibition as a therapeutic strategy to overcome PARP inhibitor resistance in high-grade serous ovarian cancer (HGSOC). The research deliverables include...

This National Cancer Institute (NCI) Project Grant award under the Cancer Biology Research program (CFDA 93.396) provides $456,103 in funding to The Feinstein Institutes for Medical Research to develop integrated risk models for endometrial cancer. The project aims to enhance early detection of endometrial cancer by determining the burden of rare genetic risk factors and creating predictive models that integrate genetic and non-genetic factors such as BMI, diabetes, and PCOS. The research will...